Ringuet Julien, Wong Grace K, Baribeau Véronique, Kalia Sunil, Brisebois Josée, Lachaine Jean
Centre de Recherche Dermatologique du Québec Métropolitain, Québec City, QC, Canada.
Incyte Biosciences Canada Corporation, Pointe-Claire, QC, Canada.
J Cutan Med Surg. 2025 May-Jun;29(3):234-242. doi: 10.1177/12034754241304683. Epub 2025 Jan 22.
Vitiligo is an autoimmune disease resulting in skin depigmentation. Treatment options are limited.
To examine disease burden and healthcare resource utilization (HCRU) among patients with vitiligo in Québec, Canada.
In this retrospective study, data were obtained from the Régie de l'Assurance Maladie du Québec (RAMQ) databases for 125,000 random individuals from January 2010 to December 2019. The () diagnostic code [709.x (other skin disorders)] with vitiligo-related treatment was used to identify patients with vitiligo. Patient characteristics and treatments, including treatment type, episodes (treatments used without discontinuation), and sequences (treatment episodes ≥30 days), were assessed. Annualized HCRU and costs (2021 adjusted) included all-cause hospitalization, emergency department visits, outpatient visits, and medications among patients with vitiligo (n = 113) and age- and sex-matched non-vitiligo controls (n = 339).
Of patients with vitiligo (mean age, 50.0 years; 68.1% female) identified using code 709.x with vitiligo-related treatment, 36.3% received ≥4 treatment episodes. Treatment patterns were heterogeneous, with 43 different sequences reported. Annualized mean outpatient visits (16.1 vs 5.5) and all-cause outpatient service costs per patient were significantly higher in the vitiligo versus the control group (CAN$1037 vs CAN$523; < .01). Total all-cause services costs were higher for patients with vitiligo in the year after versus before diagnosis (CAN$3679 vs CAN$2085; = .04).
Vitiligo is associated with significant burden and HCRU among patients in Québec, Canada, who were identified by code 709.x plus vitiligo-related treatment. Measurement of true vitiligo burden remains challenging.
白癜风是一种导致皮肤色素脱失的自身免疫性疾病。治疗选择有限。
研究加拿大魁北克省白癜风患者的疾病负担和医疗资源利用情况。
在这项回顾性研究中，从魁北克省医疗保险局（RAMQ）数据库获取了2010年1月至2019年12月期间125,000名随机个体的数据。使用与白癜风相关治疗的（）诊断代码[709.x（其他皮肤病）]来识别白癜风患者。评估了患者特征和治疗情况，包括治疗类型、发作次数（持续使用的治疗）和疗程（治疗疗程≥30天）。年度化医疗资源利用和成本（2021年调整后）包括白癜风患者（n = 113）和年龄及性别匹配的非白癜风对照组（n = 339）的全因住院、急诊科就诊、门诊就诊和药物治疗。
使用代码709.x及与白癜风相关治疗识别出的白癜风患者（平均年龄50.0岁；68.1%为女性）中，36.3%接受了≥4个疗程的治疗。治疗模式各异，报告了43种不同的疗程。白癜风组患者的年度化平均门诊就诊次数（16.1次对5.5次）和每位患者的全因门诊服务成本显著高于对照组（1037加元对523加元；P <.01）。白癜风患者诊断后一年的全因服务总成本高于诊断前（3679加元对2085加元；P = 0.04）。
在加拿大魁北克省，通过代码709.x加与白癜风相关治疗识别出的患者中，白癜风与显著的负担和医疗资源利用相关。真正的白癜风负担测量仍然具有挑战性。
